Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Debt (2016 - 2025)

Ocular Therapeutix has reported Non-Current Debt over the past 13 years, most recently at $71.3 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $71.3 million for Q4 2025, up 4.13% from a year ago — trailing twelve months through Dec 2025 was $71.3 million (up 4.13% YoY), and the annual figure for FY2025 was $71.3 million, up 4.13%.
  • Non-Current Debt for Q4 2025 was $71.3 million at Ocular Therapeutix, up from $70.6 million in the prior quarter.
  • Over the last five years, Non-Current Debt for OCUL hit a ceiling of $71.3 million in Q4 2025 and a floor of $14.9 million in Q1 2021.
  • Median Non-Current Debt over the past 5 years was $45.2 million (2023), compared with a mean of $46.0 million.
  • Biggest five-year swings in Non-Current Debt: plummeted 35.15% in 2021 and later surged 188.08% in 2024.
  • Ocular Therapeutix's Non-Current Debt stood at $25.0 million in 2021, then increased by 1.03% to $25.3 million in 2022, then soared by 160.47% to $65.8 million in 2023, then increased by 4.13% to $68.5 million in 2024, then grew by 4.13% to $71.3 million in 2025.
  • The last three reported values for Non-Current Debt were $71.3 million (Q4 2025), $70.6 million (Q3 2025), and $69.9 million (Q2 2025) per Business Quant data.